

Special Issue

Pharmacotherapy for Macular Diseases

Message from the Guest Editor

The macula plays an important role in central vision; once the macula is impaired and not appropriately treated, visual deterioration will be serious. The advent of anti-VEGF drugs greatly changed the treatment strategy for macular diseases, including neovascular age-related macular degeneration, myopic choroidal neovascularization, retinal vein occlusion, and diabetic macular edema. This Special Issue will provide new concepts, regimens, and drugs for the treatment of macular diseases. I am looking forward to your submission.

Guest Editor

Dr. Yoichi Sakurada

Department of Ophthalmology, University of Yamanashi, Chuo 409-3898, Japan

Deadline for manuscript submissions

closed (31 March 2022)



Pharmaceuticals

an Open Access Journal
by MDPI

Impact Factor 4.8

CiteScore 7.7

Indexed in PubMed



mdpi.com/si/57685

Pharmaceuticals

Editorial Office

MDPI, Grosspeteranlage 5

4052 Basel, Switzerland

Tel: +41 61 683 77 34

pharmaceuticals@mdpi.com

[mdpi.com/journal/](http://mdpi.com/journal/pharmaceuticals)

[pharmaceuticals](http://mdpi.com/journal/pharmaceuticals)





Pharmaceuticals

an Open Access Journal
by MDPI

Impact Factor 4.8
CiteScore 7.7
Indexed in PubMed



[mdpi.com/journal/
pharmaceuticals](http://mdpi.com/journal/pharmaceuticals)

About the Journal

Message from the Editor-in-Chief

Because of your expertise in the field of drug sciences, I kindly invite you to consider publishing your current work, in the form of a research article or a review, in the open access electronic journal *Pharmaceuticals*.

Pharmaceuticals is characterized by an active editorial board and a dynamic editorial staff. Manuscripts are peer-reviewed and a final decision is provided to authors within 4–6 weeks after submission. Papers are published on the web immediately after acceptance. For details on the submission process or any other matter, please do not hesitate to contact us.

We hope to handle your contribution to *Pharmaceuticals* soon.

Editor-in-Chief

Prof. Dr. Amélia Pilar Rauter

Departamento de Química e Bioquímica (DQB) e Centro de Química Estrutural (CQE), Institute of Molecular Sciences, Faculdade de Ciências, Universidade de Lisboa, Lisboa, Portugal

Author Benefits

Open Access:

free for readers, with article processing charges (APC) paid by authors or their institutions.

High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, PMC, Embase, CAPlus / SciFinder, and other databases.

Journal Rank:

JCR - Q1 (Pharmacology and Pharmacy) / CiteScore - Q1 (Pharmaceutical Science)

